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Abstract
Vaccines for COVID-19 are currently under clinical trials. These vaccines are crucial for
eradicating the novel coronavirus. Despite the potential, there exist conspiracies related
to vaccines online, which can lead to vaccination hesitancy and, thus, a longer-standing
pandemic. We used a between-subjects study design (N=572 adults in the UK and UK)
to understand the public willingness towards vaccination against the novel coronavirus
under various circumstances. Our survey findings suggest that people are more reluctant
to vaccinate their children compared to themselves. Explicitly stating the high effectiveness
of the vaccine against COVID-19 led to an increase in vaccine acceptance. Interestingly,
our results do not indicate any meaningful variance due to the use of artificial intelligence
(AI) in developing vaccines, if these systems are described to be in use alongside human
researchers. We discuss the public’s expectation of local governments in assuring the safety
and effectiveness of a future COVID-19 vaccine.
1 Introduction
The global race for a COVID-19 vaccine is on [6]. Researchers are developing vaccines against
the novel coronavirus at a record speed [9], and many of these drugs are currently under trial.
In the current pandemic, however, the hardships are not exclusive to vaccine development but
also embrace its worldwide manufacturing, distribution [56], and acceptance.
Alarmingly, protests against unpopular public health policies, such as national-wide lock-
downs, have been fueling anti-vaccine movements [5]. Misinformation, which has led to vac-
cination hesitancy during the Ebola epidemic [64], is also predominant in the current pan-
demic [18, 69]. Vaccine refusal against COVID-19 could lead to a longer-standing pandemic
and deaths that could be prevented by widespread vaccination. These public policies, which
often conflict with human rights, are necessary to the containment of the disease [12] and can
be justified by the disease’s threats to public health, for instance, under the Siracusa Princi-
ples. These movements must not be an obstacle in controlling the novel coronavirus, given the
importance of future vaccination in the disease’s eradication [15].
Epidemiological models have indicated that a vaccine is the only solution that could stop
the virus [34]. Human trials for coronavirus vaccines have begun worldwide, and scientists
expect vaccines will be made available to the population in mid or late 2021 [58].
Adopting artificial intelligence (AI) can shorten the vaccine development process, either
by reviewing possible matches for already available drugs in the market and repurposing it
for coronavirus or by assisting in the development of a new one [78]. However, AI systems
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have also raised various moral and legal questions regarding the assignment of responsibility
for their actions [21, 8]. Deploying these systems in life-or-death scenarios like medicine could
raise the stakes and lead to more complicated gaps. Therefore, we raise the question of whether
the inclusion of AI could modify public acceptance of a COVID-19 vaccine.
Early results indicate that 64% of Americans would get a COVID-19 vaccine in May 2020 [10].
Understanding the public’s willingness on this subject is critical, as vaccines are often the ul-
timate solution to lessen the burden of disease [15, 70]. It could also allow researchers and
policymakers to better prepare for vaccine hesitancy, possibly caused by misinformation [64].
The introduction of AI in biotechnology in vaccine development requires a re-evaluation of
people’s perception of newly developed vaccines.
The objective of this study is, therefore, to explore the public perception of AI-developed
vaccines, with a case-study on the vaccine against COVID-19. We also address some ethical
issues related to AI-developed vaccines by analyzing how people attribute responsibility for
the consequences of these new drugs. Our findings suggest tailored approaches to the devel-
opment of biotechnology-related policies.
2 Background
The COVID-19 Pandemic and Vaccine
COVID-19 is a newly discovered infectious disease with respiratory symptoms, caused by
SARS-CoV-2 [65], which has been declared a pandemic by the World Health Organization
(WHO) in March 2020 [69]. The disease was first found in Wuhan, China, in late 2019. Since
then, it has spread across the globe infecting, at the time of writing, over 6,000,000 people and
leading to the death of more than 350,000 patients.
While estimates of the disease’s reach and death rate have constantly been changing during
its continuous spread, early data suggests that certain groups, such as elders and patients
of pre-existing medical conditions, are more likely to fall severely ill from COVID-19. For
instance, researchers have estimated a 20 times higher death rate for those aged over 60 when
compared to their younger counterparts [62].
No specific treatment or vaccine for COVID-19 has been approved so far. As containment
measures against the disease, the WHO and national health organizations all around the world
have been promoting public policies, such as quarantines, that have led some countries to
lockdown their entire population at home. These policies are expected to impact the world
in the most diverse aspects harshly; for instance, the International Monetary Fund (IMF) has
declared that the world will most likely face the most significant economic recession since the
Great Depression [7].
Protests around the world are currently emerging to fight against these governmental de-
cisions [2]. These unpopular policies aim to contain the spread of the virus while a vaccine
is being developed. Countries that have faced the novel coronavirus earlier in the pandemic
are starting to lose some restrictions [31], such as enforced lockdowns while promoting more
lenient policies such as social distancing among their citizens. Doing so, however, has led to
second waves of infections in some countries [76].
The COVID-19 pandemic has also created a so-called infodemic [71, 18], in which a plethora
of false information regarding COVID-19 is rapidly being shared online. Studies indicate
that misinformation about Ebola has negatively influenced vaccine acceptance during its epi-
demic [64]. The WHO has also reported how misinformation has led to unfounded contro-
versies about the safety of the HPV vaccine [67]. Research analyzing the reach of anti-vaccine
movements in social media demonstrated how these groups could dominate over those pro-
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vaccine online [25]. These results, therefore, indicate that the COVID-19 infodemic might
contribute to vaccination hesitancy and refusal, an alarming note in the current pandemic.
Vaccination and Artificial Intelligence
Vaccine development is a complex process involving many steps, including preclinical, clin-
ical post-licensure development. It also requires an integration of information concerning 1)
pathogen life-cycle and epidemiology, 2) immune control and escape, 3) antigen selection and
vaccine formulation, and 4) vaccine preclinical and clinical testing [11].
Vaccination has been successful in controlling diseases [48]. The WHO estimated that
more than 17.1 million lives had been saved from measles due to widespread vaccination
from 2000 to 2015 [66]. Philanthropists have invested millions of dollars in the development
of new vaccines to combat diseases that still affect certain areas of the world, such as malaria
in Africa [29].
Nevertheless, vaccine hesitancy has been ranked in the top-10 2019 health threats by the
WHO [68]. Anti-vaccine movements still contribute to an increase in vaccine-preventable out-
breaks and epidemics by promoting hesitancy. These harmful fronts sway vaccine acceptance
and are often influenced by conspiracy theories [26], lack of trust in the health system, past
experiences with vaccination, and other factors [17].
Much research has been devoted to understanding the acceptance of vaccines. For instance,
scholars have used both quantitative and qualitative methods to explore vaccine decisions [32,
41, 16]. Hesitancy to get vaccinated can be caused by a broad range of factors, including the
compulsory nature of vaccines, unfamiliarity with vaccine-preventable diseases, and lack of
trust in corporations and public health organizations [54]. Previous work has also indicated
differences in vaccine acceptance across cultural and ethnic groups [73, 13]. Regarding the
past 2009 H1N1 pandemic, scholars have also addressed factors influencing vaccine decisions
within the general population [50] and health care workers [74].
Widespread vaccination can result in herd immunity, under which a specific population
becomes resistant to the disease if a majority of its citizens develop immunity against it [1].
Vaccine refusal could lead to a longer-standing disease, causing many more deaths than if
vaccination was widespread. Therefore, the development of a COVID-19 vaccine is urgently
needed to overcome the crisis in the pandemic situation.
AI has entered the field of medicine, in which much of its research has been dedicated to
the diagnosis and treatment of diseases [46, 36, 40]. Regarding the COVID-19 pandemic, AI
is currently being used to diagnose cases from CT scans and symptoms [35, 79, 24], to predict
the spread of the virus [77], and in many other areas. For instance, an AI-based search system
has also identified an existing drug that could effectively combat the disease [52].
Vaccine development is also employing AI systems. For instance, SAM (i.e., Search Algo-
rithm for Ligands), an AI program designed to identify compounds to improve the human
immune system, has independently developed a highly effective flu vaccine [42]. While AI
could shorten the drug discovery process and improve the global health system by identifying
new and more effective vaccines, it could also arguably contribute to the spread of anti-vaccine
movements. Scholars have discussed how the general public might develop trust towards AI
systems differently in comparison to their human counterparts [72], and therefore employing
AI in the vaccine development might increase vaccine hesitancy and refusal, making more
difficult the fight against vaccine-preventable diseases.
3
Responsibility Issues for Artificial Intelligence’s Actions
The deployment of AI systems in various sectors of society has raised numerous ethical, legal,
and moral questions. Researchers have proposed the concept of Responsible AI [14], in which
developers are to take responsibility for all steps of the development and deployment of their
systems. Scholars, however, have also discussed how doing so might not be viable given the
unpredictability and complexity of self-learning and autonomous AI systems [21].
The concept of responsibility has various related meanings [59, 63], all of which with its
requirements for attribution [61]. Scholars have previously discussed whether AI and other
stakeholders could satisfy these conditions, concluding that no entity fulfills all requirements
for responsibility attribution [37, 33].
Similarly to the problem of many hands [60] in attributing responsibility to collective
agents, responsibility attribution for AI actions suffers from the issue of “many things” [8]: AI
is a collection of various entities, technologies, and smaller interacting structures that makes
the assignment of responsibility more complex. In medicine, an area where consequences are
often a matter of life and death, successfully ascribing responsibility for mistakes and negative
outcomes is an important step towards developing safe and trustworthy systems.
In the area of medicine, scholars have shown that the public assigns responsibility and
punishment for negative outcomes to both AI and human doctors, although to different ex-
tents [38]. Autonomous cars are also blamed, to a lesser degree, than human drivers in the
occurrence of accidents [3].
Previous research has also proposed the existence of various moral and legal gaps arising
from the deployment of AI systems. The responsibility gap, for instance, is created by the lack
of capacity to predict the behavior of self-learning machines by the manufacturer or opera-
tor [44], which results in these entities not being able to be held morally and legally respon-
sible for outcomes. Similarly, the accountability gap arises from a distance between the opera-
tor/manufacturer and the machine, making difficult the attribution of “causality to either the
physical person or company that is behind the (electronic) agent” [28]. Finally, the punishment
gap is a public contradiction in which the general public desires to punish AI agents for their
wrongful actions even though people are aware that doing so is not feasible in the current legal
landscape [39].
3 Research Questions
This study asks the following research questions (RQ):
RQ1: How willing are people to get vaccinated against COVID-19 during the pandemic?
RQ2: How does willingness to get vaccinated change depending on the recipient?
Understanding public willingness to accept an AI-developed vaccine can contribute to the
fight against future anti-vaccine movements, so public officials and health care workers can
better adapt to when these new vaccines are available. In our study, we include AI into the
development of vaccines in two different forms: an AI system 1) independently identifying
a compound for a COVID-19 vaccine and 2) assisting (human) researchers in the process of
developing it. While a lot of research has been devoted to developing autonomous AI systems
(e.g., autonomous vehicles), they are often still deployed in collaboration with human agents
(e.g., Tesla’s autopilot requires human input). Vaccine development would be no exception to
the rule, and deploying these systems would at first require human oversight. RQ3 raises the
question of whether public willingness to get vaccinated might be influenced by the employ-
ment of AI in vaccine development.
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RQ3: Does including AI in the process of developing a COVID-19 vaccine change peo-
ple’s willingness to get vaccinated?
News coverage influences public perception of various and disjoint issues [19], such as
attitudes towards African Americans [20], perceptions of educational institutions [27], and
political campaigns [51]. Medicine, and more specifically, vaccination, can also be influenced
by news reports. For instance, there is evidence that local newspapers have previously influ-
enced vaccine acceptance [43]. Previous work has also shown that parents who have read or
heard negative information regarding vaccines tend to delay childhood vaccination [57].
Hence, in this study, we raise the question of whether the approach used by news media to
introduce the effectiveness or side effects of a future COVID-19 vaccine can influence public
willingness to get vaccinated.
RQ4: Does willingness to get vaccinated against COVID-19 change based on how the
effectiveness and possible side-effects are introduced?
Finally, we take a descriptive approach and aim to understand how the public assigns re-
sponsibility for the consequences, positive or otherwise, of the development of vaccines in
RQ5. Inspired by previous work, we address responsibility as blame (or credit) and pun-
ishment (i.e., liability) and question to what extent people assign these variables to entities
involved in the development of vaccines, such as the AI itself, researchers, and the company
who developed the AI. In this study, we also tackle awareness, i.e., knowledge of one’s ac-
tions and consequences, as an important aspect of responsibility attribution. Knowledge has
been proposed as one requirement for blame assignment [61], while awareness is an important
aspect of civil and criminal liability (e.g., foreseeability in civil law, mens rea in criminal law).
RQ5: How are responsibility and awareness attributed to the entities involved in the
development and deployment of the COVID-19 vaccine?
4 Methodology
Study Design
We address our proposed research questions via a cross-sectional study design, which em-
ployed a between-subjects design, in which participants were presented two different news-
like vignettes out of nine (3×3) combinations. It is important to note that the survey was
conducted in the midst of the pandemic. This study has been approved by the first authors’
institution review board.
Survey
The survey started by briefly introducing COVID-19 and the number of confirmed cases and
deaths at the time of the study. The participants were then asked three questions addressing
whether they had any close contact with COVID-19 suspected or confirmed patients. We also
measured the participants’ personal concerns regarding the disease. For each participant, we
averaged their answers to four questions designed to quantify people’s concern regarding the
personal consequences of COVID-19 and their perceived likelihood of infection. The partic-
ipants reported their level of concern using a slider in the range of -1 and 1. The proposed
scale reported an acceptable level of internal consistency (Cronbach’s α=0.71). The questions
are presented in Appendix A.
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We quantify the participants’ willingness to accept a COVID-19 vaccine by first presenting
a stimulus similar to a realistic newspaper article (see Appendix B). The proposed vignettes
introduced the beginning of trials of a vaccine against the novel coronavirus. We designed
three versions of articles that solely differed in who was the entity that led to the development
of the vaccine.
In the first vignette, the vaccine was completely developed by a collaboration of human
researchers from various institutes; we call this treatment group human-developed (vaccine).
In the other two proposed stimuli, an AI system was introduced in the development of the
vaccine. The human-AI collaboration scenario introduced SAM (Search Algorithm for Ligands),
the AI program responsible for the first AI-developed vaccine [42]. In this article, SAM was
the entity that identified a set of compounds that were effective against COVID-19. Human
researchers, working alongside SAM, distinguished the best one out of the set and synthesized
the vaccine. The final article also introduced SAM; the scenario, however, presented the AI
program as the entity who found the most effective compound and explicitly posited that the
human researchers only synthesized the vaccine. We address this final scenario as AI-developed
(vaccine).
The participants were randomly assigned an article. After reading it, the participants were
asked how willing they were to get this vaccine to 1) themselves, 2) their child, and 3) their
elders. The respondents were also asked to what extent they were worried about getting this
new vaccine. All questions were presented in random order, and respondents answered them
using a slider in the range of -1 and 1.
As an attention check question, the participants were then presented a question asking
them who was able to find a compound for the COVID-19 vaccine, according to the article.
The participants picked the best answer out of four options: a team of researchers, an AI
program, a team of researchers with the help of the AI program, and the general public. We
discuss how this attention check was used to remove inattentive responses below.
The survey subsequently presented another randomly selected news-like vignette to the
participants. The news article introduced a future scenario in mid-2021, in which a COVID-
19 vaccine has finally been approved and made available to the public. Each stimulus framed
the effectiveness or side effects of the vaccine in a different manner. The positive news article in-
troduced the vaccine as highly effective in developing immunity against the novel coronavirus.
The article explicitly compared the effectiveness of this vaccine to the average effectiveness of
childhood vaccines according to the WHO1. On the other hand, the negative news-like stim-
ulus discussed how there had been some reports of mild side effects, such as headaches and
fever, on recipients of this new vaccine. The vignette concluded by stating that no complica-
tions had been reported and that the vaccine was the most effective way to combat the disease.
We also designed a control stimulus, which excluded any mentions to the effectiveness or the
side effects of the vaccine.
After reading the second vignette, the participants were asked the extents to which they
would assign responsibility and awareness to various entities involved in the development and
deployment of the vaccine. Participants assigned to the human-developed vaccine scenario were
presented three entities to which they were asked to attribute these variables: the researchers
who developed the vaccine (shown in plots as Human), the government (Gov), and the health
care worker who administers the vaccine (Wrkr). In the case of a human-AI collaboration or a
AI-developed vaccine, respondents were additionally asked to assign responsibility and aware-
ness to SAM (AI), its developing company (Comp) and its main programmer (Progr).
Had participants been assigned to a negative stimulus, they were asked the levels of blame,
1“Most routine childhood vaccines are effective for 85% to 95% of recipients.” Available at https://www.who.
int/vaccine safety/initiative/detection/immunization misconceptions/en/index2.html
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awareness, and punishment they would assign to all entities for the side effects of the vac-
cine. The participants assigned to a positive and control stimulus, however, attributed credit
(i.e., praise) and awareness for the effectiveness and development of the COVID-19 vaccine,
respectively. Entities were presented one at a time and in random order to all participants.
The responses were recorded on a scale of -1 to 1 using a slider. Finally, participants were
asked the same willingness- and worry-related questions from the initial stimulus.
Finally, we used the Medical Maximizer-Minimizer Scale (MMMS) [55] to measure to what
extent the participants were “medical maximizers” or “minimizers”. ”Medical maximizers”
are those individuals predisposed to seek health care for minor problems, while “minimizers”
would rather avoid health care treatment unless extremely necessary. Responses to all ten
questions reported a high level of internal consistency (Cronbach’s α = 0.86). After answer-
ing all questions, the participants were asked demographic questions, such as their age and
political views.
Participants and Recruitment
We conducted our survey on Prolific, a survey sampling firm, in mid-April 2020. We recruited
630 participants from the US and UK. Prolific allowed us to recruit participants representing
current sex, age, and ethnicity US and UK demographic distributions.
Figure 1: Cumulative distribution of average personal concern regarding COVID-19. The ver-
tical lines indicate the division between categories of those less concerned, those in the “middle
of the road”, and those more concerned.
Respondents were removed from the analysis had they failed the attention check question
or did not spend enough time reading both stimuli. Participants were considered to fail the
attention check had they chosen the general public as the entity who identified the vaccine
compound. We also discarded respondents who did not indicate the participation of an AI
program even though they had been assigned a AI-developed or human-AI collaboration sce-
nario. Finally, we removed participants that either spent less than half its reading time2 or
more than six minutes reading each of the news-like stimuli. Our final dataset consisted of
572 responses, out of which 287 and 285 respondents are US and UK residents, respectively.
We categorize participants into three groups: those less concerned about the disease (LC),
those very concerned about it (VC), and finally, those in the “middle of the road” (MR). We
divide participants into three quantiles of personal concern based on their responses to the
concern-related questions. Figure 1 shows the cumulative distribution of responses and their
2We calculated the reading time of our articles using https://wordcounter.net/.
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(a) LC=Less concerned, MR=Middle of the road,
VC=More concerned regarding the disease.
(b) Min=Medical minimizers, MR=Middle of the
road, Max=Medical maximizers.
Figure 2: Willingness to accept a COVID-19 vaccine depending on the recipient.
categorization. Throughout this paper, we discuss people’s personal concerns using these de-
fined categories.
We employ a similar method to categorize respondents between “medical maximizers” and
“minimizers”. Respondents were divided into three categories of similar range. For instance,
respondents with an MMMS value of less than -0.333 were categorized as “medical minimiz-
ers”; we consider “maximizers” those who reported an MMMS response of over 0.333.
Data Analysis
We analyze our data by conducting multi-way ANOVA tests for addressing the existence of sta-
tistically significant differences across treatment groups, and Tukey honestly significant differ-
ence (HSD) tests for posthoc pairwise comparisons between them. Interaction terms between
treatment groups are included in all significance tests with the exception of the demographic
analysis. All plots, unless otherwise stated, present the group’s means and their respective
95% confidence intervals.
5 Results
RQ1-2: Willingness to Get Vaccinated Against COVID-19
Our first research question broadly addressed the overall willingness to accept a vaccine to
combat the current pandemic. Participants of this study were marginally predisposed to ac-
cept a new vaccine against the novel coronavirus, with a reported median and mean willing-
ness of 0.170 and 0.143, respectively.
Figure 2a shows a lower overall willingness to vaccinate children (F=31.731, P <.001) re-
gardless of the respondent’s level of concern regarding COVID-19 (F=0.617, P=.650) or their
predisposition to seek health care (F=0.183, P=.947). The participants revealed a lower accep-
tance of the vaccine for children when compared to their willingness to vaccinate themselves
(∆=0.227, P <.001) and their elders (∆=0.240, P <.001). The participants, however, indicated
no difference in their inclination to get personally vaccinated against COVID-19 and the pre-
disposition to take their elders to get the vaccine (P >.05). We did not find any differences
between willingness of US and UK participants.
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(a) LC=Less concerned, MR=Middle of the road,
VC=More concerned regarding the disease.
(b) Min=Medical minimizers, MR=Middle of the
road, Max=Medical maximizers.
Figure 3: Willingness to accept a COVID-19 vaccine depending on the entity who led the
development of the vaccine.
The participants’ level of concern regarding the novel coronavirus is positively correlated
with the overall willingness to accept a newly developed COVID-19 vaccine to all recipients
(F=20.799, P <.001). Those more concerned about the disease were more predisposed to get
vaccinated in relation to those less concerned about it (∆=0.221, P <.001) or in the middle of
the road (∆=0.119, P <.005). Moreover, those in the middle of the road were more willing to
accept the vaccine than less concerned respondents (∆=0.102, P <.01).
Figure 2b shows that medical maximizers also reported a higher willingness to get vacci-
nated (F=12.853, P <.001) against COVID-19 when compared to medical minimizers (∆=0.232,
P <.001) and those in the center of the MMMS scale (∆=0.131, P <.05). Moreover, medical min-
imizers were also marginally less willing to get vaccinated vis--vis those with less extreme
predisposition or aversion to seeking health care (∆=0.101, P <.05).
Finally, we also analyzed whether there exists any difference in vaccination acceptance
depending on the respondents’ previous experiences with vaccines and their contact with
COVID-19. Plots of the overall acceptance of the vaccine, regardless of the recipient, based
on these attributes are presented in Appendix E. The participants who have received all their
countries’ required vaccines reported a higher acceptance (F=26.795, P <.001) in comparison
to those who have only received some (∆=0.196, P <.001) or none of them (∆=0.219, P <.001).
Moreover, having an acquaintance or themselves previously infected with COVID-19 also in-
creased willingness to get vaccinated (F=7.387, ∆=0.083, P <.01). Lastly, those who were resid-
ing in cities where COVID-19 had at least infected one resident also reported lower hesitancy
towards the vaccine (F=23.516, ∆=0.183, P <.001).
RQ3: Acceptance of AI in the Development of Vaccines
Figure 3a shows the mean vaccination acceptance scores regardless of the recipient, depend-
ing on who was the entity that led its development: an AI program, a team of researchers, or a
collaboration between both. Participants’ willingness to get vaccinated altered with the inser-
tion of AI in the development of vaccines (F=8.250, P <.001). Our findings indicate an overall
lower willingness to get vaccinated if the vaccine’s compound was independently found by an
AI rather than solely by human researchers (∆=0.135, P <.001).
Our results do not show any significant interaction between the participants’ level of con-
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Figure 4: Assignment of blame, credit, and awareness to all entities involved in the develop-
ment and deployment of the COVID-19 vaccine depending on how the consequences of the
vaccine were framed.
cern regarding the disease and the entity who identified the vaccine’s compound in predicting
their willingness to accept the vaccine (P >.05). On the other hand, medical maximizers in-
dicated a higher willingness to accept an AI-developed vaccine than medical minimizers (see
Figure 3b, ∆=0.286, P <.05) and those in the middle of the road (∆=0.248, P <.005).
RQ4: Framing of the Effects of the Vaccine
Our fourth research question examined whether the form used to introduce the consequences
of the COVID-19 vaccine modifies their responses to how willing they would be in accepting
it in the future. We present the outcomes of the vaccine in two different forms: discussing its
high effectiveness against the novel coronavirus or reporting some side effects of the vaccine.
As a method of dealing with a possible subject-expectancy effect caused by asking similar
questions in sequence, we also design a control group in which the consequences of the vaccine
are not explicitly introduced.
Our results indicate a significant difference across treatment groups (F=31.903, P <.001).
A more positive framing of the consequences of the COVID-19 vaccine increased overall will-
ingness to get vaccinated in comparison to the control group (∆=0.182, P <.001). Interestingly,
a more negative framing also reported a positive willingness-change in comparison to the con-
trol stimulus (∆=0.113, P <.001).
The entity who had developed the vaccine according to the first article presented to the par-
ticipants influenced how much they modified their acceptance of the vaccine (F=4.986, P <.01).
The respondents assigned to the human-AI collaboration stimulus reported a marginally higher
positive change in overall willingness to get vaccinated in relation to those assigned to a AI-
developed (∆=0.061, P <.05) or a human-developed (∆=0.069, P <.05) vaccines.
Finally, the participants’ initial willingness was strongly correlated to how much people
modified their inclination to get vaccinated upon an intervention (F=110.949, P <.001). Par-
ticipants in the lower tercile of vaccine acceptance reported a higher willingness-change when
compared to those in both the center and upper terciles of willingness to get vaccinated against
COVID-19 (∆=0.150, ∆=0.345, respectively, both P <.001). Those who reported an average
willingness, i.e., in the center tercile, were more affected by the stimulus than respondent’s in
the upper tercile (∆=0.194, P <.001). Therefore, those initially less willingness to accept a vac-
cine are overall more likely to increase their inclination to get vaccinated (Pearson’s r=-0.338,
95% conf [-0.379, -0.295], P <.001).
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Figure 5: Assignment of punishment to all entities involved in the development the COVID-19
vaccine.
RQ5: Responsibility for the Vaccine
Figure 4 shows participants’ level of ascribed blame, credit, and awareness to all entities ad-
dressed in our study. Even though liability could be considered one of the various meanings of
responsibility [61], we address blame and praise as responsibility and punishment as liability
below. Participants in this stddy assign vastly less blame for the side effects of the vaccine than
credit for its development and effectiveness across all entities (F=802.406, P <.001). This de-
crease in responsibility, however, is, to a lesser extent, for the government. The overall respon-
sibility ascribed to AI is similar to that attributed to its programmer (P ¿.05). The AI program
is assigned marginally less blame and credit than its human counterpart (∆=0.086, P <.001).
Our results also indicate no difference whatsoever in the level of responsibility attributed to
AI and humans depending on whether they independently or collaboratively identified the
vaccine’s compound (see Appendix D, both P >.05).
The level of awareness ascribed to all entities is overall lower in the case of negative fram-
ing of the consequences of the vaccine (F=59.552, P <.001). Therefore, people believed entities
are less aware of the possible side effects of a vaccine than of its effectiveness (∆=0.115, P <.001)
and its development in general (∆=0.118, P <.001). The level of awareness assigned to an AI
is lower than that assigned to all entities (all P <0.001). People also presumed the government
should be as aware as the researchers who developed it regardless of the consequences of the
vaccine (P >0.05). Even though the overall awareness assigned to all entities by the human-AI
collaboration treatment group was marginally lower than in the case of an human-developed
vaccine (∆=0.084, P <.001), our results suggest no significant difference between the attribu-
tion of awareness to AI and the human researchers depending on who was the entity who
identified the vaccine’s compound.
Figure 5 shows to what extent participants assigned punishment for the side effects of the
vaccine. Participants were only asked these questions had they been assigned to the negative
treatment group.The overall punishment assigned to all entities is vastly lower than responsi-
bility (i.e., blame and credit), with the government being ascribed marginally higher liability
than all entities excluding the AI’s developing company (all P <.05).
11
6 Discussion
RQ1: Those Concerned About COVID-19 Are More Inclined to Vaccinate Against
It
Our results indicate that the personal level of concern regarding the novel coronavirus and
the participants’ predisposition to seek health care influence the participants’ acceptance of
the vaccine. Those more concerned about it are more willing to accept it; similarly, medical
maximizers also report a higher level of willingness to get vaccinated against COVID-19. The
participants who have reported a lower level of concern regarding COVID-19 demonstrated a
borderline willingness to get vaccinated against it (µ=0.034). More alarmingly, medical min-
imizers indicated an even higher hesitancy towards the vaccine (µ=0.015). Even though the
current pandemic has greatly affected the population surveyed (e.g., at the time of the study,
the US was the country with the highest number of deaths), certain layers of society appear
to hesitate vaccination against COVID-19 still. This trend is especially distinguishable among
those participants who had not been received all nationally required vaccines or had not had
any close contact with the disease.
Our results, therefore, suggest that future public policies should strongly promote the vac-
cination against the novel coronavirus once (and possibly before) the vaccine has been ap-
proved. Citizens who are less concerned about the disease, with history of vaccination hesi-
tancy or refusal, and those groups less affected by the virus are less likely to get vaccinated
against COVID-19. This is in line with the Health Belief Model, a classic theory which iden-
tified perceived susceptibility and severity as factors for engaging with health behavior [53].
Governments could develop health policies to promote vaccination for COVID-19 based on
this finding. For example, national campaigns which increase the awareness of risk and side
effects of COVID-19 might increase the perceived susceptibility and severity. These efforts
could also increase compliance with preventive measures, such as social distancing, if tar-
geted at those less concerned. For instance, an earlier study has found that younger people are
less concerned about the disease and demonstrate lower compliance with these measures [45].
RQ2: People Hesitate to Vaccinate Children Against COVID-19
Our findings indicate that people are less willing to vaccinate their children in comparison to
their willingness to vaccinate themselves or their elders. This finding is intriguing considering
that the elders have been hit the hardest by the COVID-19 pandemic [62]. While our results
indicate that people are aware that the oldest layer of society must also be vaccinated against
the novel coronavirus, people hesitate to vaccinate the youngest.
We hypothesize that this result might be influenced by the false claims that children are re-
sistant or even immune to COVID-19 [23, 49]. These rumors have not only been disseminated
by the general population but also world leaders and public figures in various countries [47, 4].
Those who defend more lenient quarantine policies often argue that the youngest layer of soci-
ety should not be isolated due to the lower risk of complications. Defenders of these proposals,
however, neglect the possibility of spread from the youngest to the elderly, i.e., those more sus-
ceptible to complications due to COVID-19. Moreover, the burden of diseases caused by the
long-term impact from the coronavirus such as cardiovascular complications [75] and mental
health issues [30] could decrease the quality of life and increase healthcare cost in children for
a prolonged period of time. Our findings suggest that the government and health organiza-
tions, such as local CDCs and the WHO, should also highlight the importance of and promote
the vaccination against COVID-19 for the youngest layers of society as a form of control of the
disease once a vaccine is available to the population.
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RQ3: Human-AI Collaborative Vaccines Do Not Affect Vaccination Acceptance
Including AI systems in the development of vaccines might have an effect on vaccine accep-
tance. RQ3 addressed this hypothesis by asking whether a vaccine independently or collabo-
ratively created by an AI modifies the respondent’s willingness to get vaccinated vis--vis vac-
cines solely created by human researchers. Our results indicate that an AI-developed vaccine
has a lower acceptance rate in comparison to those developed by a team of human researchers.
However, our findings do not show any significant difference in willingness to get vaccinated
if the vaccine was developed by both an AI and human researchers collaboratively.
While the public might not be entirely trustful of vaccines solely developed by AI, our re-
sults suggest that explicitly introducing the role of these systems alongside human researchers
in the development of collaborative vaccines does not modify vaccine acceptance. AI might
prove to shorten drug discovery time and therefore improve the global health system [42].
Therefore, the inclusion of these systems in this area of medicine, if the humans are not yet
completely removed from the process, should not contribute to vaccine hesitancy and refusal
while advancing the process of vaccine development.
RQ4: Introducing the Effectiveness of the Vaccine Can Decrease Hesitancy
Explicitly introducing the effectiveness of a new vaccine has shown to positively influence
willingness to get vaccinated in comparison to only reporting the availability of the vaccine
to the population (i.e., the control group in our study). Our results suggest, therefore, that
governments might choose to promote vaccination through an advertisement of the efficacy of
a coronavirus vaccine once it has been approved.
We also examined whether a more negative stance while reporting the outcomes of the vac-
cine could negatively influence people’s willingness to get vaccinated. Our results indicate a
marginal positive overall willingness-change in comparison to the control group. We hypoth-
esize that this is caused by the form of how the stimulus was designed. First, the consequences
were not extremely serious or harmful; we explicitly addressed the side effects saying that they
did not lead to any complications and disappeared after a few hours. Second, we also reported
at the end of the articles that this vaccine was the most effective and safest way to combat
the pandemic, so our intervention would not promote anti-vaccination feelings. Moreover, the
participants assigned to the human-AI collaboration scenario reported an even higher positive
change in vaccine acceptance in such treatment group.
Our results suggest that those who are initially less willing to vaccinate report a greater
positive change in their acceptance of the vaccine. Therefore, public promotion campaigns, es-
pecially if focused on advertising vaccines’ effectiveness against the novel coronavirus, could
influence those less willing to get vaccinated, an important step towards stopping the pan-
demic.
Finally, a human-AI collaborative vaccine has shown to be malleable in terms of public
willingness. We thus posit that people are open to human-AI collaborations in this field, par-
ticularly if such vaccines are proved to be safe (i.e., approved). Alongside our results indicating
that participants’ initial acceptance of the vaccine did not differ between vaccines solely de-
veloped by humans and those collaboratively created, our findings indicate that including AI
into the development of vaccines could be extremely beneficial to the process without much
public hesitancy or backlash.
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RQ5: Awareness-Lacking AI Is Praised for Its Vaccine and the Government’s Role
in Approving Safe Vaccines
Participants in this study assigned a high level of credit to the AI system for its development
and effectiveness. In terms of blame, moreover, AI was attributed to similar levels to that of
human researchers had both of them been involved in the process. In agreement with previous
work [39], the participants regard AI systems as responsible for their actions, although they
are not to be considered aware of their actions. Even though marginally less responsibility is
attributed to these systems in comparison to their human counterparts, their blame or credit
for the outcomes of the vaccine is similar to those ascribed to their main programmers.
The government and the team of researchers involved in the development of the vaccine
are ascribed to the most awareness. The government, even though it is assigned less credit
for its development and effectiveness, is attributed to similar levels of blame and awareness to
the humans who developed the COVID-19 vaccine. Moreover, the government, alongside the
AI’s developing company, was assigned the most punishment for its side effects. Therefore,
our results indicate a public attribution of responsibility to the government in this process,
especially if the vaccine has any side effects. This exemplifies the governmental role in testing
and approving safe and effective treatments for the current pandemic.
Our results suggest that people attribute responsibility for the actions of an AI to the sys-
tem itself, as well as to other entities involved in the development and deployment of these
systems. This supports the proposal of an ”extended agency theory,” [22] where responsi-
bility and “moral agency would be (jointly) distributed over both human and technological
artifacts,” a previously proposed response to the various responsibility gaps raised by the de-
ployment of AI [21].
7 Concluding Remarks
The current study indicates three main findings that suggest how governments might want
to focus their COVID-19 vaccination policies in the future. First, the participants exhibited a
lower willingness to vaccinate children in comparison to accepting it for themselves or their
elders. Second, those less concerned about the disease or more doubtful about seeking health-
care (i.e., “medical minimizers”) are significantly more hesitant about the vaccine. Citizens
with previous history of vaccination hesitancy and communities less affected by the virus also
report a lower willingness to accept the COVID-19 vaccine. Finally, our results suggest that
promotion campaigns that highlight the effectiveness of the vaccine against the pandemic
might increase willingness to get vaccinated, especially to the ones who are initially more
hesitant about it.
The inclusion of AI in the process of development of new vaccines could influence pub-
lic willingness to get vaccinated, possibly fueling harmful anti-vaccination movements. Our
results indicate that while a vaccine whose compound was independently identified by an AI
could lead to marginally higher hesitation, a human-AI collaboration does not modify public
willingness to get vaccinated. Our results also suggest that human-AI collaborative vaccines
are more malleable in terms of acceptance after reports of the vaccine’s approval. Therefore,
the inclusion of AI systems, alongside human stakeholders, in this area could highly benefit
the development of new vaccines without an increase in vaccination hesitancy or refusal.
The study participants assigned high levels of praise and blame to the AI systems involved
in the development of a vaccine, although they are attributed to a lower degree of awareness
regarding the vaccine’s outcomes. Our findings also suggest the public assignment of a role to
governments in making sure that vaccines are safe and effective after approval alongside other
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human stakeholders. The government, however, is not highly praised for its development but
only blamed or punished for their side effects.
Studies addressing public willingness to vaccinate against COVID-19 should not be re-
stricted to ours, but also be expanded in terms of populations, size, and reach. Vaccination
acceptance might also change throughout the pandemic. For instance, misinformation could
lead to vaccine refusal, as found during the Ebola epidemic [64]. It is important to note that
these results might not be generalizable to other vaccines, as the case for the novel coron-
avirus is, by definition, biased due to the current pandemic situation. Future studies should
address how our findings generalize to other diseases with different levels of prominence. Ad-
ditionally, we have included AI into the development of vaccines by its role in identifying its
compound, as it has been done in the past [42]; however, results might be dependent on an
AI’s specific role, an essential line of study is not only vaccine development but all areas where
AI is currently being deployed.
In conclusion, our study indicates the government’s crucial role in the approval process of
the COVID-19 vaccine. The public believes that the government should be aware of the vac-
cine’s consequences and blamed if they are not ideal; however, it should not be praised for its
development. Tailored health policies to increase the perceived susceptibility and perceived
severity could be helpful in increasing the number of people willing to accept a COVID-19
vaccine. These campaigns should especially promote vaccination among children, as people
are less willing to vaccine the youngest layer of society against the novel coronavirus. A possi-
bility would be to focus these promotion efforts on highlighting the effectiveness of the vaccine
against the pandemic.
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Appendix A
Our survey participants were asked the following four questions as a measure of their per-
sonal concern regarding COVID-19. The questions reported an acceptable level of internal
consistency (Cronbach‘s α=0.71). The responses to these questions were averaged for each
respondent and participants were categorized into three groups identified by the distribution
terciles, as explained in “Data Cleaning” Section.
1. How likely are you to become ill with COVID-19?
2. How severe do you think the economic consequences of COVID-19 will be to you?
3. If you become infected with COVID-19, how likely do you believe it is that you might
fall severely ill or die from it?
4. How concerned are you about the COVID-19 transmission?
Appendix B
The participants were presented a realistic news article addressing who was the entity that
identified the compound used in the COVID-19 vaccine. Figure 6 shows the AI-developed,
human-AI collaboration, and human-developed vignettes presented to the respondents. Each
participant was randomly assigned to a news article.
Appendix C
The respondents were presented to another randomly selected news article differing in how
the effectiveness and side effects of the COVID-19 vaccine were framed. Figure 7 shows the
positive, negative, and control articles presented to them.
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(a) AI-developed vaccine (b) Human-AI collaboration
(c) Human-developed vaccine
Figure 6: News-like stimuli presented to participants before the first set of willingness and
worry questions. The articles differ in who was the entity who led the development of the
COVID-19 vaccine.
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(a) Positive framing introducing the high effective-
ness of the vaccine
(b) Negative framing describing reports of side ef-
fects due to the vaccine
(c) Control framing which does not explicitly dis-
cuss the vaccine’s effectiveness or side effects
Figure 7: News-like stimuli presented to participants before the second set of willingness and
worry questions. The articles differ in how they frame the consequences of the vaccine.
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Appendix D
Figure 8 shows the extent to which the respondents attributed responsibility and awareness
to AI and human researchers depending on who was the entity who identified the compound
used in the COVID-19 vaccine. While AI systems are attribute lower awareness and marginally
less responsibility, our results suggests no difference between treatment groups.
Figure 8: Assignment of blame, credit, and awareness to the AI and the human researchers
who developed the COVID-19 vaccine.
Appendix E
Figure 9 shows willingness to accept a COVID-19 vaccine depending on the respondents’ pre-
vious experiences with vaccines (left), whether there had been COVID-19 cases in their city
(middle), and whether an acquaintance or themselves had been infected by the novel coron-
avirus (right).
Figure 9: Acceptance of the COVID-19 vaccine depending on the respondents’ vaccination
history and contact with the novel coronavirus. All plots present willingness to vaccinate
regardless of the recipient.
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